John T Randolph

8PUBLICATIONS
19CO-AUTHORS
Cheminformatics and quantitative structure-activity relationshipsGene and molecular therapyMolecular targetsBiomolecular modelling and designPharmaceutical delivery technologies
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (8)

|May 25, 2026
Discovery of Potent and Orally Bioavailable Novel Cluster of Differentiation 38 (CD38) Small Molecule Inhibitors.

|May 23, 2024
Anti-TNF Thioester Glucocorticoid Antibody-Drug Conjugate Fully Inhibits Inflammation with Minimal Effect on Systemic Corticosterone Levels in a Mouse Arthritis Model.

Christopher C Marvin, Adrian D Hobson, Michael J McPherson

|Mar 06, 2023
Discovery of a Potent Chloroacetamide GPX4 Inhibitor with Bioavailability to Enable Target Engagement in Mice, a Potential Tool Compound for Inducing Ferroptosis In Vivo.

John T Randolph, Matthew J O'Connor, Fei Han

|Nov 17, 2022
Discovery of ABBV-3373, an Anti-TNF Glucocorticoid Receptor Modulator Immunology Antibody Drug Conjugate.

Adrian D Hobson, Michael J McPherson, Martin E Hayes

|Sep 04, 2020
Prodrug Strategies to Improve the Solubility of the HCV NS5A Inhibitor Pibrentasvir (ABT-530).

John T Randolph, Eric A Voight, Stephen N Greszler

|Apr 15, 2018
Highlights of the Structure-Activity Relationships of Benzimidazole Linked Pyrrolidines Leading to the Discovery of the Hepatitis C Virus NS5A Inhibitor Pibrentasvir (ABT-530).

Rolf Wagner, John T Randolph, Sachin V Patel

Pageof 2

Frequent Collaborators

3 joint publications

Adrian D Hobson

3 joint publications

Christopher C Marvin

3 joint publications

Meena V Patel

2 joint publications

John K Pratt